Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
Fulcrum Therapeutics (Nasdaq: FULC) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:00 a.m. ET. The presentation will provide a corporate overview of the company, which focuses on genetically defined rare diseases. Investors can access a live audio webcast on Fulcrum's Investor Relations website, with an archived replay available for 90 days. The company is advancing treatments for conditions like facioscapulohumeral muscular dystrophy and sickle cell disease.
Details
News Market Reaction – FULC
The recorded move for FULC in the trading session of this news was -0.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 a.m. ET.
A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 90 days.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
Please visit www.fulcrumtx.com.
Contact:
Christi Waarich
Director, Investor Relations
and Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.